Enliven Therapeutics (NASDAQ:ELVN) CFO Benjamin Hohl Sells 6,018 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 6,018 shares of the company’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $43.80, for a total transaction of $263,588.40. Following the completion of the transaction, the chief financial officer owned 51,000 shares of the company’s stock, valued at approximately $2,233,800. The trade was a 10.55% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics Stock Performance

ELVN opened at $45.96 on Tuesday. The stock has a market capitalization of $2.80 billion, a P/E ratio of -27.52 and a beta of 0.29. Enliven Therapeutics, Inc. has a one year low of $14.78 and a one year high of $48.53. The business’s 50-day simple moving average is $41.82 and its 200-day simple moving average is $31.76.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. On average, equities research analysts forecast that Enliven Therapeutics, Inc. will post -1.71 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on ELVN shares. HC Wainwright lifted their price objective on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Stifel Nicolaus initiated coverage on Enliven Therapeutics in a report on Tuesday, June 9th. They issued a “buy” rating and a $60.00 price target on the stock. Guggenheim started coverage on shares of Enliven Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $80.00 price objective on the stock. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $63.40.

Institutional Investors Weigh In On Enliven Therapeutics

Several large investors have recently made changes to their positions in ELVN. KBC Group NV acquired a new stake in shares of Enliven Therapeutics in the first quarter valued at about $38,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after buying an additional 594 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after acquiring an additional 930 shares during the last quarter. Quantbot Technologies LP raised its holdings in shares of Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after purchasing an additional 1,434 shares during the period. Finally, Tower Research Capital LLC TRC raised its stake in Enliven Therapeutics by 194.3% during the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock worth $106,000 after acquiring an additional 3,490 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.